These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 29742186)

  • 1. Factors Affecting Dermatologists' Use of a 31-Gene Expression Profiling Test as an Adjunct for Predicting Metastatic Risk in Cutaneous Melanoma.
    Svoboda RM; Glazer AM; Farberg AS; Rigel DS
    J Drugs Dermatol; 2018 May; 17(5):544-547. PubMed ID: 29742186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of a 31-gene Expression Profiling Test for Cutaneous Melanoma on Dermatologists' Clinical Management Decisions.
    Farberg AS; Glazer AM; White R; Rigel DS
    J Drugs Dermatol; 2017 May; 16(5):428-431. PubMed ID: 28628677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management Decisions Made by Physician Assistants and Nurse Practitioners in Cutaneous Malignant Melanoma Patients: Impact of a 31-Gene Expression Profile Test.
    Mirsky R; Prado G; Svoboda R; Glazer A; Rigel D
    J Drugs Dermatol; 2018 Nov; 17(11):1220-1223. PubMed ID: 30500144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Gene Expression Profile Testing on the Management of Squamous Cell Carcinoma by Dermatologists.
    Rebeca T; Giselle P; Litchman GH; Rigel DS
    J Drugs Dermatol; 2019 Oct; 18(10):980-984. PubMed ID: 31584775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.
    Zager JS; Gastman BR; Leachman S; Gonzalez RC; Fleming MD; Ferris LK; Ho J; Miller AR; Cook RW; Covington KR; Meldi-Plasseraud K; Middlebrook B; Kaminester LH; Greisinger A; Estrada SI; Pariser DM; Cranmer LD; Messina JL; Vetto JT; Wayne JD; Delman KA; Lawson DH; Gerami P
    BMC Cancer; 2018 Feb; 18(1):130. PubMed ID: 29402264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit.
    Grossman D; Okwundu N; Bartlett EK; Marchetti MA; Othus M; Coit DG; Hartman RI; Leachman SA; Berry EG; Korde L; Lee SJ; Bar-Eli M; Berwick M; Bowles T; Buchbinder EI; Burton EM; Chu EY; Curiel-Lewandrowski C; Curtis JA; Daud A; Deacon DC; Ferris LK; Gershenwald JE; Grossmann KF; Hu-Lieskovan S; Hyngstrom J; Jeter JM; Judson-Torres RL; Kendra KL; Kim CC; Kirkwood JM; Lawson DH; Leming PD; Long GV; Marghoob AA; Mehnert JM; Ming ME; Nelson KC; Polsky D; Scolyer RA; Smith EA; Sondak VK; Stark MS; Stein JA; Thompson JA; Thompson JF; Venna SS; Wei ML; Swetter SM
    JAMA Dermatol; 2020 Sep; 156(9):1004-1011. PubMed ID: 32725204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test.
    Hsueh EC; DeBloom JR; Lee J; Sussman JJ; Covington KR; Middlebrook B; Johnson C; Cook RW; Slingluff CL; McMasters KM
    J Hematol Oncol; 2017 Aug; 10(1):152. PubMed ID: 28851416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma.
    Keller J; Schwartz TL; Lizalek JM; Chang ES; Patel AD; Hurley MY; Hsueh EC
    Cancer Med; 2019 May; 8(5):2205-2212. PubMed ID: 30950242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Gene Expression Profiling on Decision-Making in Clinically Node Negative Melanoma Patients after Surgical Staging.
    Schuitevoerder D; Heath M; Cook RW; Covington KR; Fortino J; Leachman S; Vetto JT
    J Drugs Dermatol; 2018 Feb; 17(2):196-199. PubMed ID: 29462228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of a Noninvasive 2-Gene Molecular Assay for Cutaneous Melanoma and Effect on the Decision to Biopsy.
    Ferris LK; Jansen B; Ho J; Busam KJ; Gross K; Hansen DD; Alsobrook JP; Yao Z; Peck GL; Gerami P
    JAMA Dermatol; 2017 Jul; 153(7):675-680. PubMed ID: 28445578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Utility of Dermoscopy and 31-Gene Expression Profiling by Dermatology Providers in Melanoma Management Care.
    Witkowski A; Lee C; Latour E; Vetto J; Ludzik J
    J Drugs Dermatol; 2022 Dec; 21(12):1347-1352. PubMed ID: 36468965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria.
    Gastman BR; Gerami P; Kurley SJ; Cook RW; Leachman S; Vetto JT
    J Am Acad Dermatol; 2019 Jan; 80(1):149-157.e4. PubMed ID: 30081113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy.
    Gerami P; Cook RW; Russell MC; Wilkinson J; Amaria RN; Gonzalez R; Lyle S; Jackson GL; Greisinger AJ; Johnson CE; Oelschlager KM; Stone JF; Maetzold DJ; Ferris LK; Wayne JD; Cooper C; Obregon R; Delman KA; Lawson D
    J Am Acad Dermatol; 2015 May; 72(5):780-5.e3. PubMed ID: 25748297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integration of a 31-Gene Expression Profile Into Clinical Decision-Making in the Treatment of Cutaneous Melanoma.
    Scott AM; Dale PS; Conforti A; Gibbs JN
    Am Surg; 2020 Nov; 86(11):1561-1564. PubMed ID: 32755379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy?
    Mays MP; Martin RC; Burton A; Ginter B; Edwards MJ; Reintgen DS; Ross MI; Urist MM; Stromberg AJ; McMasters KM; Scoggins CR
    Cancer; 2010 Mar; 116(6):1535-44. PubMed ID: 20108306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attitudes of patients with cutaneous melanoma toward prognostic testing using the 31-gene expression profile test.
    Ahmed K; Siegel JJ; Morgan-Linnell SK; LiPira K
    Cancer Med; 2023 Jan; 12(2):2008-2015. PubMed ID: 35915969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma.
    Kruper LL; Spitz FR; Czerniecki BJ; Fraker DL; Blackwood-Chirchir A; Ming ME; Elder DE; Elenitsas R; Guerry D; Gimotty PA
    Cancer; 2006 Nov; 107(10):2436-45. PubMed ID: 17058288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of a prognostic 40-gene expression profiling test on clinical management decisions for high-risk cutaneous squamous cell carcinoma.
    Litchman GH; Fitzgerald AL; Kurley SJ; Cook RW; Rigel DS
    Curr Med Res Opin; 2020 Aug; 36(8):1295-1300. PubMed ID: 32372702
    [No Abstract]   [Full Text] [Related]  

  • 19. Gene expression profiling in melanoma: past results and future potential.
    Knackstedt RW; Knackstedt T; Gastman B
    Future Oncol; 2019 Mar; 15(7):791-800. PubMed ID: 30453756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sentinel lymph node biopsy for cutaneous melanoma: the Stanford experience, 1997-2004.
    Berk DR; Johnson DL; Uzieblo A; Kiernan M; Swetter SM
    Arch Dermatol; 2005 Aug; 141(8):1016-22. PubMed ID: 16103331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.